Every zero-result search is logged — it is how we decide what to curate next.
Also: NN9487 · NN 9487 · NNC0487-0111 · 3051672-09-1
Four separate measurements, never averaged. Independent evidence counts only studies with no sponsor attached. Methodology version v2.0-2026-10 · how we grade evidence
Being developed to produce large reductions in body weight in adults with overweight or obesity and to improve glycaemic control with weight loss in adults with type 2 diabetes. Novo Nordisk’s interest is in combining incretin and amylin pharmacology in a single molecule rather than as a co-formulation, which is what CagriSema does. Zenagamtide is the assigned international non-proprietary name; the compound was developed as, and is still widely called, amycretin.
It is not approved anywhere for any indication and has not been filed anywhere. Novo’s own ADA 2026 material states that zenagamtide "is not approved in the United States. Safety and efficacy are not established, and there is no guarantee that these investigational medicines will become commercially available." Subcutaneous phase 3 trials began in 2026 and the oral form had not started phase 3; no phase 3 results have been reported for any indication.
The entire human efficacy database is phase 1 and phase 2: 125 people subcutaneously, 144 orally, and 262 in type 2 diabetes. Maximum controlled exposure anywhere is 36 weeks. Anyone citing the headline 24.3% weight-loss figure should know it comes from a 125-person phase 1b/2a in which the placebo arms gained weight in three of four comparisons, not from a pivotal trial. The phase 2b used a fixed dose-escalation design that permanently discontinued participants who could not tolerate their assigned dose, which tends to flatter the tolerability reported.
Amycretin is sold online by "research peptide" vendors. Those products are not the studied product and the data below do not describe them.
At a glance
A single molecule containing covalently linked GLP-1 and amylin analogue peptides, so one agent agonises both the GLP-1 receptor — appetite regulation and glucose-dependent insulin secretion — and the amylin receptor, which drives satiation through a non-incretin pathway. It has been developed in both a once-weekly subcutaneous and a once-daily oral formulation, the oral form using salcaprozate sodium as a permeation enhancer. Placebo-controlled human trials show dose-dependent weight loss and HbA1c reduction, so the pharmacodynamic consequence is established. The dual-receptor attribution is not: no human study has dissected the GLP-1 versus amylin contribution of this single molecule. The reported findings on feeding-related brain regions and on preferential reduction of energy-dense diet consumption are rat data.
Dated determinations, each flagged for whether it is final and whether it covers safety only. A safety review is not an efficacy finding, and most reporting in this category conflates the two.
Novo Nordisk’s own ADA 2026 press material states: "CagriSema, zenagamtide, IcoSema, and efruxifermin are not approved in the United States. Safety and efficacy are not established, and there is no guarantee that these investigational medicines will become commercially available." Subcutaneous zenagamtide entered phase 3 for obesity with the AMAZE programme in the first quarter of 2026, HF-POLARIS in heart failure in the second quarter, and a cardiovascular outcomes trial (AMBIENCE) was slated for the fourth quarter; the oral form was listed as "Phase 3 to be initiated" with no date, and the AMBITION diabetes programme was to start in the second half of 2026. No phase 3 results have been reported for any indication.
Educational information only
Educational information only. Not medical advice, not a diagnosis, and not a substitute for your clinician. Never start, stop, or change a prescription medication based on anything you read here. We do not sell, prescribe, dispense or recommend any medication, peptide or supplement, and we do not link to anyone who does. If you are having a medical emergency, call 911.
Published by Nu Link, 10111 Clodine Rd, Richmond, TX 77407.